Defence Therapeutics has announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for the company’s Canadian patent application no. 3,201,103 for its vaccine technology.
Canadian patent no. 3,201,103 (the ‘103 patent) covers Defence’s revolutionary vaccine technology, which significantly enhances the immunogenicity of protein subunit vaccines.
The groundbreaking vaccine technology improves efficacy and potentially lowers the antigen dose required to trigger a protective immune response.
Commenting on the development, Sébastien Plouffe, CEO of Defence Therapeutics, said: “The fact that the CIPO decided to allow the ‘103 patent without issuing any examination report, and only one month after substantive examination started, is a strong testament to the innovative nature of Defence’s vaccine technology, as well as an acknowledgement by the Canadian government of the strength of Defence’s scientific data.”
The ‘103 patent also includes essential information on matter claims encompassing any protein subunit vaccine that uses Defence’s vaccine technology.
It also covers claims regarding the manufacture and use of vaccines in fighting cancer and infectious diseases. The counterpart US patent no. 11,291,717 was granted to Defence a few months ago.
Reinforcing Defence’s patent portfolio
With solid patent protection already obtained in key vaccine markets, including the US and Canada, Defence is poised to capitalise on these patents to swiftly establish comprehensive patent coverage in other vital markets, such as Europe and Asia.
The recent issuance of the ‘103 patent fortifies Defence’s national patent portfolio, aligning seamlessly with the company’s goals of progressing their innovative clinical vaccine candidates.
Furthermore, it opens up new prospects for licensing and partnerships, particularly with manufacturers of approved protein subunit vaccines aiming to enhance effectiveness and extend the patent lifespan of their products.
